Clinical Trial Update: AUY922 in Patient With Stage IV NSCLC [Phase 2]

View source ↗

Summary

Completed Phase 2 clinical trial update of the HSP90 inhibitor luminespib (AUY922) in a patient with stage IV non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• luminespib (luminespib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED